Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VERITAS: Intensification Strategies for Metastatic Neuroblastoma
NCT03165292Phase 2Terminated
- Sponsor
- Gustave Roussy
- Start
- Oct 2018
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, open-label trial in neuroblastoma comparing 131I-mIBG + Topotecan with High-dose Thiotepa (2 arms). Primary endpoint: Event Free Survival at 3 years. Started Oct 2018; status: terminated.
02
Drugs
Iobenguane I-131thiotepa
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT03165292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03165292.